Trial Profile
A cross-sectional study assessing patients with Plasma calprotectin as a biomarker of active synovitis in rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Sarilumab (Primary) ; Tocilizumab (Primary) ; Tofacitinib (Primary)
- Indications Rheumatoid arthritis; Synovitis
- Focus Therapeutic Use
- 10 Jan 2022 New trial record